Abstract: A rapidly disintegrating tablet comprising a therapeutically effective amount of a DPP-IV inhibitor and an acid-base couple having mineral content below the daily intake limits is disclosed. The rapidly disintegrating tablet has a sodium content less than 10 mg and a potassium content less than 15 mg. A process for preparation of the rapidly disintegrating tablet comprising the DPP-IV inhibitor is also disclosed.

Abstract: The present invention relates to effervescent compositions of Metformin and optionally other anti-diabetic agents and processes for preparation thereof. More particularly provides an effervescent composition comprising Metformin, an acid and a base such that the composition is free of affirmatively added binders and granulating solvents. The effervescent composition of the present invention has retained carbon dioxide content of at least 90% of the input blend.

Abstract: The present disclosure relates to a process for preparing granules from an input material or a powder material. The process comprises feeding the input material for granulation in the processor using one or more powder feeders, introducing steam as a granulation activating agent in the processor, granulating the input material in presence of the steam to form granules, and optionally collecting the granules from a discharge zone of the processor, wherein feed rate of the steam into the processor is determined based on feed rate of the input material into the processor.

Abstract: The present invention relates to a granular composition comprising essentially Tenofovir, wherein the composition is devoid of an excipient. Tenofovir granules of the present invention are prepared in twin-screw processor such that the content of total impurities in the prepared granules is less than 2.0%.

Abstract: The present disclosure concerns effervescent compositions and methods of making and using the same. In some embodiments, the disclosed effervescent compositions are formed from an input blend comprising an acid and a base by granulating the input blend in a twin-screw processor. The granules formed from the input blend can be formed by an in situ granulating agent, which can be a portion of the acid that melts during granulation. In some embodiments, the effervescent compositions can be made using a twin-screw processor comprising an intake zone for receiving an input blend comprising an acid and a base; a granulation initiation zone for melting only a portion of the acid to serve as an in situ granulating agent; a granulation completion zone for granulating the input blend; and an outlet for discharging the granules.

Abstract: The present invention discloses stable, solid oral pharmaceutical composition comprising Lanthanum carbonate having more than 6 molecules of water per molecule of lanthanum carbonate and pharmaceutically acceptable carriers or diluents, wherein said carrier or diluent excludes monosaccharide/s or disaccharide/s, such that the composition has comparable in-vitro dissolution profile similar to that of FOSRENOL®. Also disclosed is a wet granulation process for making the same.

Abstract: Pharmaceutical compositions comprising a plurality of formulated particles containing at least one active ingredient and at least one pharmaceutically acceptable excipient, granulated with a granulating composition containing at least one pharmaceutical excipient.

Abstract: The present invention discloses stable, solid oral pharmaceutical composition comprising Lanthanum carbonate having more than 6 molecules of water per molecule of lanthanum carbonate and pharmaceutically acceptable carriers or diluents, wherein said carrier or diluent excludes monosaccharide/s or disaccharide/s, such that the composition has comparable in-vitro dissolution profile similar to that of FOSRENOL®. Also disclosed is a wet granulation process for making the same.

Abstract: A method for plastid transformation of a plant cell includes providing a delivery construct for transferring a passenger construct into a plant cell plastid for expression of a foreign DNA of interest therein. The delivery construct includes a nucleotide sequence under the control of a suitable promoter, for encoding at least one fusion protein which is a chloroplast transit peptide and a DNA binding domain. The passenger construct includes a nucleotide sequence encoding at least one foreign protein of interest or fragment thereof to be expressed in the plant cell, under the control of a plastid-specific promoter.

Abstract: A process for preparing pure omeprazole Form B, and compositions containing omeprazole Form B.

Abstract: Compositions and/or formulations comprising solifenacin or a salt thereof and processes for preparing the same. Certain compositions and formulations contain a stable amorphous form of solifenacin succinate.

Abstract: The present invention relates to pharmaceutical formulations of atorvastatin or its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, polymorphs or their mixtures; and processes for preparing the same, and their methods of use, treatment and administration. Further, the present invention relates to pharmaceutical compositions comprising an acid-solubility-enhanced form of atorvastatin or its salts.

Abstract: Compositions comprising amorphous substituted benzimidazole compounds.

Abstract: Pharmaceutical compositions comprising a plurality of formulated particles containing at least one active ingredient and at least one pharmaceutically acceptable excipient, granulated with a granulating composition containing at least one pharmaceutical excipient.

Abstract: Pharmaceutical compositions comprising aprepitant, wherein aprepitant solubility in aqueous media is enhanced.

Abstract: Pharmaceutical compositions comprising montelukast or pharmaceutically acceptable salts, solvates, polymorphs, enantiomers or mixtures thereof.

Abstract: Pharmaceutical compositions comprising mesalamine, wherein the compositions are free of a liphophilic matrix, and processes for preparing pharmaceutical compositions comprising mesalamine and being free of a liphophilic matrix.

Abstract: Stable pharmaceutical compositions comprising zafirlukast and pharmaceutically acceptable salts, solvates, polymorphs, enantiomers or mixtures thereof, together with one or more pharmaceutically acceptable polymers, and processes for their preparation.

Abstract: The invention relates to pharmaceutical compositions having polymers that release paroxetine in a controlled manner for a prolonged or sustained period of time. An embodiment of the invention provides enhanced bioavailability controlled release pharmaceutical compositions comprising paroxetine or its pharmaceutically acceptable salts, which enables a reduction in its orally administered dose.

Abstract: Controlled release tablets comprising ciprofloxacin, with hardness and friability of the said tablets ranges between 10 to 70 kiloponds and less than 2% respectively, the compositions releasing at least 80 percent of the total amount of the ciprofloxacin into a pH 1.2 aqueous dissolution medium within about 1 hour.